How does Testosterone Propionate bind to the androgen receptor at the molecular level?

After ester hydrolysis releases free testosterone, it diffuses into target cells and binds the ligand-binding domain of the intracellular androgen receptor with low nanomolar affinity. The resulting testosterone-AR complex undergoes a conformational change, translocates to the nucleus, and docks with androgen-response elements on gene promoters — initiating transcription of genes governing muscle protein synthesis, red blood cell production, and nitrogen retention.

What role does DHT conversion play in Testosterone Propionate's androgenic effects?

5-alpha reductase converts a portion of free testosterone to dihydrotestosterone intracellularly. DHT binds the androgen receptor with roughly three times the affinity of testosterone itself, amplifying androgenic signalling in tissues with high 5αR expression — including skeletal muscle, scalp, and prostate. This conversion distinguishes testosterone esters from non-5αR-substrate androgens and explains the stronger androgenic character compared to 19-nor compounds.

Why does Testosterone Propionate's receptor affinity differ from synthetic anabolic steroids like nandrolone?

Nandrolone (a 19-nor compound) is a poor 5αR substrate, so it does not amplify to a high-affinity DHT metabolite in target tissues. Testosterone propionate, being native testosterone, undergoes full 5αR-mediated conversion, producing the broader androgenic tissue signal characteristic of endogenous androgens — resulting in stronger androgenic side-effect potential but also fuller androgenic drive in neural and neuromuscular tissue.

What is the practical dosing advantage of GenTec Test-P 150's 150mg/ml concentration compared to standard preparations?

At 150mg/ml — the highest concentration in its product category — GenTec Test-P 150 delivers a full 150mg dose in a single 1ml draw, whereas a 100mg/ml preparation requires 1.5ml for the same dose. Smaller oil-volume injections reduce intramuscular depot pressure and localised discomfort, particularly relevant for high-frequency administration schedules where injection-site tolerance accumulates over weeks.

How should GenTec Test-P 150's 10ml vial be stored after opening, and how many doses does it provide?

After first puncture, the multi-dose 10ml vial should be stored at room temperature away from direct light and used within 28 days; refrigeration between 2°C and 8°C extends usable life but requires warming to body temperature before injection to reduce solution viscosity. At a common 100mg dose, the 10ml vial supplies ten full doses; at 150mg per administration, it provides approximately six to seven injections — making volume planning straightforward before cycle start. (2) angle_used

New Formula

GenTec

Test-P 150 150mg/ml 10ml Vial by GenTec

Name: Test-P 150 150mg/ml 10ml Vial by GenTec
Brand: GenTec
SKU: INJ-TPRO-GEN-150-009
Price: 34.00 EUR
Availability: InStock

GenTec Test-P 150 is a high-concentration androgenic injectable supplying 150mg of Testosterone Propionate per millilitre — formulated to engage androgen receptors with the full binding affinity of endogenous testosterone, accelerated by the propionate ester's rapid hydrolysis kinetics. At 150mg/ml, each millilitre delivers 50% greater active compound than conventional 100mg/ml preparations, compressing effective dosing volumes without sacrificing androgenic precision. Batch integrity is confirmed through HPLC quantitative analysis and LAL endotoxin assay; GMP-qualified manufacturing partners supply the API under documented qualification audits.

€34.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Full-affinity androgen receptor agonism matching endogenous testosterone's ligand-binding potency
DHT-pathway activation amplifies androgenic signalling in 5-alpha reductase–expressing tissues
150mg/ml concentration reduces per-dose oil volume by one-third versus conventional 100mg/ml products
Rapid ester hydrolysis enables plasma-level response within the first injection cycle
Multi-dose 10ml vial format supports complete short-ester protocols without mid-cycle resupply
ARE-mediated transcription upregulates contractile protein synthesis and satellite-cell recruitment simultaneously
HPLC-verified and LAL endotoxin-tested batches confirm concentration accuracy and sterile-processing compliance

Phase	Dosage	Note
AR Saturation — Introductory Period (Weeks 1–2)	75–100mg every other day (EOD)	Lower end chosen to establish receptor occupancy baseline and assess individual androgenic sensitivity before escalating; 150mg/ml concentration means 0.5–0.67ml per draw
Sustained Receptor Activation — Maintenance (Weeks 3–10)	100–150mg EOD	Consistent EOD spacing maintains stable free-testosterone plasma levels sufficient for continuous ARE-mediated gene activation; 1ml draw delivers full 150mg at label concentration
Androgenic Wind-Down — Final Week	75mg EOD	Tapering reduces receptor occupancy gradually, easing the hormonal transition toward PCT; propionate ester clearance within days allows SERM initiation shortly after final injection

Key takeaways

Understand that free testosterone binds androgen receptors with low nanomolar affinity to drive gene transcription.
Anticipate amplified androgenic signalling from 5-alpha reductase conversion to DHT in target tissues.
Choose 150mg/ml concentration to minimise injection oil volume per dose without reducing androgenic output.
Track androgen receptor occupancy timelines to align injection frequency with sustained anabolic signalling.
Verify each GenTec batch via HPLC and LAL endotoxin documentation before beginning any protocol.

Testosterone Propionate as an Androgen Receptor Agonist: What GenTec Test-P 150 Actually Does

GenTec Test-P 150 is an oil-based injectable steroid in which Testosterone Propionate — testosterone attached to a short propanoic acid ester — functions as a direct, high-affinity agonist of the intracellular androgen receptor (AR). The free testosterone liberated after ester hydrolysis binds the AR's ligand-binding domain with a dissociation constant (Kd) in the low nanomolar range, matching the affinity of endogenous testosterone measured in human myocyte studies. This receptor occupancy triggers nuclear translocation of the AR-ligand complex, where it engages androgen-response elements (AREs) on target gene promoters to upregulate contractile protein synthesis, erythropoietic signalling, and satellite-cell recruitment.

DHT Conversion and Tissue-Specific Receptor Activation

Testosterone itself is a partial substrate for 5-alpha reductase (5αR), and a meaningful proportion of circulating free testosterone undergoes intracellular conversion to dihydrotestosterone (DHT) in androgen-sensitive tissues. DHT binds the androgen receptor with approximately three times the affinity of testosterone as established in competitive radiobinding assays, producing amplified transcriptional output in tissues rich in 5αR — notably skeletal muscle, skin, and the prostate. Compared to non-5αR-substrate androgens such as nandrolone, testosterone propionate therefore generates a broader tissue-level androgenic signal, including full androgenic drive in neural tissue where DHT concentration correlates with motivation and recovery signalling.

AR Transactivation Kinetics and the 150mg/ml Concentration Advantage

Testosterone propionate's ester is cleaved by plasma and tissue esterases within hours of intramuscular deposition, releasing bioavailable free testosterone that reaches peak plasma concentration within 24–36 hours post-injection (pharmacokinetic data referenced from classical Testosterone Propionate PK studies, e.g., Nieschlag & Behre, Testosterone: Action, Deficiency, Substitution, 4th ed.). GenTec Test-P 150 supplies this free testosterone pulse at 150mg/ml — meaning a 1ml injection delivers a dose that would require 1.5ml from a standard 100mg/ml preparation. Reduced injection volume per dose lowers the oil-vehicle bolus deposited intramuscularly, a relevant consideration for users managing injection-site tolerance across multi-week protocols.

Three core semantic facts govern the mechanism: free testosterone activates the androgen receptor directly in skeletal muscle cells; 5-alpha reductase converts testosterone to DHT for amplified AR binding in specific tissues; and sustained AR occupancy drives anabolic gene expression via ARE-mediated transcription. These are not additive effects but sequential steps in a single receptor-signalling cascade — understanding them allows practitioners to anticipate both the anabolic outcomes and the androgenic side-effect profile associated with Test-P 150 precisely.

Usage

Confirm the vial label reads 150mg/ml and cross-reference the batch number against GenTec's HPLC certificate of analysis before drawing.
Warm the vial briefly in your palm for 60 seconds to reduce solution viscosity — at 150mg/ml, oil-vehicle thickness can slow draw speed through a fine-gauge needle.
Use a 23–25G, 1–1.5-inch needle for intramuscular injection into the gluteal, vastus lateralis, or deltoid site; rotate sites across each EOD injection to limit local AR-overload and injection-site irritation.
Draw the calculated volume precisely — at 150mg/ml, each 0.1ml corresponds to exactly 15mg of testosterone propionate, enabling fine-grained dose control aligned with your target AR occupancy.
Inject slowly over 15–30 seconds to distribute the oil bolus evenly within the muscle fascia; rapid injection concentrates the depot and increases localised discomfort.
Log each injection (date, site, dose, batch number) to track receptor-activation schedules and maintain accountability for any side-effect emergence correlated with dosing intervals.

Warnings

Contraindications: Test-P 150 is contraindicated in individuals with androgen-sensitive prostate or breast carcinoma, as AR agonism accelerates proliferation in these tissues. Active polycythaemia, severe hepatic impairment, or known hypersensitivity to any constituent (including the oil vehicle or preservative system) precludes use. Pregnancy is an absolute contraindication.

Side Effects: Androgenic effects include acne, accelerated scalp hair loss in genetically predisposed individuals, and prostate tissue stimulation — all mediated by DHT-pathway AR activation. Estrogenic effects (gynecomastia, water retention) arise from aromatase conversion of excess free testosterone; an aromatase inhibitor such as anastrozole or exemestane should be available. Haematocrit elevation via erythropoietic AR signalling requires periodic monitoring to manage thromboembolic risk.

Monitoring: Serum testosterone (total and free), SHBG, LH, FSH, haematocrit, PSA (in males over 40), and lipid panels should be assessed at baseline and at weeks 4–6 of any cycle. Liver enzyme panels (ALT, AST) are prudent even for injectable androgens given systemic metabolic load. Blood pressure monitoring is warranted given androgenic effects on renal sodium retention.

PCT: Because Testosterone Propionate's ester clears relatively quickly, a selective estrogen receptor modulator (SERM) — typically nolvadex (tamoxifen) 20–40mg/day or clomiphene 50mg/day — can be initiated within 3–5 days of the final injection. PCT duration of 4 weeks is standard; re-testing of LH, FSH, and endogenous testosterone at PCT completion determines whether extended support is required.

Frequently asked questions

How does Testosterone Propionate bind to the androgen receptor at the molecular level?: After ester hydrolysis releases free testosterone, it diffuses into target cells and binds the ligand-binding domain of the intracellular androgen receptor with low nanomolar affinity. The resulting testosterone-AR complex undergoes a conformational change, translocates to the nucleus, and docks with androgen-response elements on gene promoters — initiating transcription of genes governing muscle protein synthesis, red blood cell production, and nitrogen retention.
What role does DHT conversion play in Testosterone Propionate's androgenic effects?: 5-alpha reductase converts a portion of free testosterone to dihydrotestosterone intracellularly. DHT binds the androgen receptor with roughly three times the affinity of testosterone itself, amplifying androgenic signalling in tissues with high 5αR expression — including skeletal muscle, scalp, and prostate. This conversion distinguishes testosterone esters from non-5αR-substrate androgens and explains the stronger androgenic character compared to 19-nor compounds.
Why does Testosterone Propionate's receptor affinity differ from synthetic anabolic steroids like nandrolone?: Nandrolone (a 19-nor compound) is a poor 5αR substrate, so it does not amplify to a high-affinity DHT metabolite in target tissues. Testosterone propionate, being native testosterone, undergoes full 5αR-mediated conversion, producing the broader androgenic tissue signal characteristic of endogenous androgens — resulting in stronger androgenic side-effect potential but also fuller androgenic drive in neural and neuromuscular tissue.
What is the practical dosing advantage of GenTec Test-P 150's 150mg/ml concentration compared to standard preparations?: At 150mg/ml — the highest concentration in its product category — GenTec Test-P 150 delivers a full 150mg dose in a single 1ml draw, whereas a 100mg/ml preparation requires 1.5ml for the same dose. Smaller oil-volume injections reduce intramuscular depot pressure and localised discomfort, particularly relevant for high-frequency administration schedules where injection-site tolerance accumulates over weeks.
How should GenTec Test-P 150's 10ml vial be stored after opening, and how many doses does it provide?: After first puncture, the multi-dose 10ml vial should be stored at room temperature away from direct light and used within 28 days; refrigeration between 2°C and 8°C extends usable life but requires warming to body temperature before injection to reduce solution viscosity. At a common 100mg dose, the 10ml vial supplies ten full doses; at 150mg per administration, it provides approximately six to seven injections — making volume planning straightforward before cycle start. (2) angle_used

Manufacturer

GenTec's approach to active pharmaceutical ingredient (API) sourcing for Test-P 150 centres on the traceability of raw testosterone propionate powder from synthesis to finished vial — a supply-chain discipline the company formalises through documented supplier qualification rather than in-house synthesis. API origin is subject to incoming testing protocols that verify chemical identity, purity grade, and absence of process-related impurities before the material enters filling operations; certificate-of-analysis cross-referencing against pharmacopoeial specifications (BP/EP standards for testosterone esters) forms the evidentiary backbone of each batch release. The sourcing philosophy reflects a deliberate commercial stance: GenTec treats the API origin audit as the first critical quality control point, on the premise that no downstream manufacturing process can correct deficiencies introduced at raw-material level. For a compound like Testosterone Propionate — where concentration accuracy at 150mg/ml directly governs the androgenic dose delivered per millilitre — the starting-material specification is not a formality but a pharmacologically consequential variable.

Product details

Brand	GenTec
Active ingredient	testosterone propionate
Also known as	Testosterone Propionate, Test P, Testovis, Test-P 150, GenTec Testosterone Propionate
Strength	150 mg
Form	Vial
Pack size	1 piece
Item number	INJ-TPRO-GEN-150-009

Reviews

No reviews yet. Be the first to review this product.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

Propandrol 100mg/ml 10x1ml Ampoules by Balkan Pharmaceuticals

Established Brand

Propandrol 100mg/ml 10x1ml Ampullen by Balkan Pharmaceuticals

Propandrol is a pharmaceutical-grade injectable testosterone, historically the first esterified testosterone derivative to reach clinical practice, formulated by Balkan Pharmaceuticals as Testosterone Propionate at 100 mg per millilitre in individually sealed 1 ml glass ampoules. The propionate ester — first synthesised and trialled in the 1930s — remains the benchmark short-acting testosterone form against which all later esters have been compared by endocrinologists and sports scientists alike. Batch-level sterility and potency are confirmed through validated HPLC quantification and LAL endotoxin testing; every ampoule leaving the Chișinău facility carries a traceable lot code under EU GMP Annex 1 requirements.

€36.00

Optimal Dosage

Propha-Testosterone 100mg/ml 10ml Vial by Beligas Pharmaceuticals

Propha-Testosterone by Beligas Pharmaceuticals supplies Testosterone Propionate at 100 mg/ml in a sterile 10 ml multi-dose vial — an intramuscular injectable whose short-ester architecture routes the compound directly into systemic circulation, bypassing the hepatic first-pass degradation that renders oral testosterone formats pharmacokinetically inferior. Each vial supports precise volumetric dose control across recomposition and performance phases, with plasma testosterone maintained consistently within an active physiological window throughout the cycle. Batch release is contingent on passing a dual analytical gate: reversed-phase HPLC potency confirmation and LAL endotoxin clearance, both documented per lot under GMP-compliant manufacturing conditions.

€35.00

Testopin-100 100mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Fast Acting

Testopin-100 100mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Testopin-100 is a short-ester testosterone injectable — Testosterone Propionate at 100 mg/ml — engineered for rapid onset of action, delivering measurable anabolic activity within 24–48 hours of the first injection due to Propionate's characteristically brief half-life of approximately 2–3 days. Each ampoule in this 10×1ml format provides a precisely dosed, single-use sterile unit that supports frequent administration schedules designed to maintain stable blood concentrations. Quality is assured through validated HPLC potency testing and LAL endotoxin screening at batch release; every ampoule meets pharmaceutical-grade sterility criteria before leaving the BM Pharmaceuticals facility.

€38.00

High Concentration

PropiTrex 150mg/ml 10ml Vial by Concentrex Labs

PropiTrex by Concentrex Labs delivers Testosterone Propionate at 150 mg/ml in a sterile 10 ml multi-dose vial, purpose-engineered for athletes who schedule injections around specific training days and precise clock windows. Each millilitre carries 50% more active androgen than standard 100 mg/ml propionate preparations, compressing effective dose volumes and making frequent, day-specific administration more practical. Sterility and potency are confirmed through LAL endotoxin testing and HPLC quantification at batch release; every vial exits the Concentrex Labs facility only after passing documented aseptic-processing controls.

€35.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00